PepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.

SeaStar Medical announced progress in its NEUTRALIZE-AKI pivotal trial for acute kidney injury treatment, reaching over 60% enrollment with 125 of 200 anticipated patients and 16 clinical trial sites activated.

SeaStar Medical, a commercial-stage healthcare company, announced that it will report its Q1 2025 financial results and host a conference call on May 14, 2025. The company's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA.

SeaStar Medical Holding Corporation, a healthcare company focused on transforming treatments for critically ill patients, announced that it will report its fourth quarter and year-end 2024 financial results on March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress.

SeaStar Medical Holding Corporation announced that a 14th site has been activated for its NEUTRALIZE-AKI pivotal trial, which is evaluating the safety and efficacy of its Selective Cytopheretic Device (SCD) in treating acute kidney injury (AKI) in intensive care unit patients. The company estimates a significant market opportunity for the SCD in ...